← All trials

NCT04627285

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 31, 2020
Primary completion
Oct 31, 2025
Completion date
Oct 31, 2025
First posted
Nov 13, 2020
Last posted
Dec 8, 2020
Enrollment
100
Arms / groups
1 / —
Source
AACT · ingestion pipeline

Sponsors

  • UCBLead sponsor
  • UCBStudy director

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.